1. Home
  2. SLS vs ELA Comparison

SLS vs ELA Comparison

Compare SLS & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLS
  • ELA
  • Stock Information
  • Founded
  • SLS 2012
  • ELA 1965
  • Country
  • SLS United States
  • ELA United States
  • Employees
  • SLS N/A
  • ELA N/A
  • Industry
  • SLS Biotechnology: Pharmaceutical Preparations
  • ELA Consumer Specialties
  • Sector
  • SLS Health Care
  • ELA Consumer Discretionary
  • Exchange
  • SLS Nasdaq
  • ELA Nasdaq
  • Market Cap
  • SLS 185.3M
  • ELA 198.1M
  • IPO Year
  • SLS N/A
  • ELA N/A
  • Fundamental
  • Price
  • SLS $1.69
  • ELA $7.53
  • Analyst Decision
  • SLS Strong Buy
  • ELA Strong Buy
  • Analyst Count
  • SLS 1
  • ELA 1
  • Target Price
  • SLS $7.00
  • ELA $9.00
  • AVG Volume (30 Days)
  • SLS 2.0M
  • ELA 54.6K
  • Earning Date
  • SLS 11-12-2025
  • ELA 11-04-2025
  • Dividend Yield
  • SLS N/A
  • ELA N/A
  • EPS Growth
  • SLS N/A
  • ELA 34.09
  • EPS
  • SLS N/A
  • ELA 0.33
  • Revenue
  • SLS N/A
  • ELA $198,354,109.00
  • Revenue This Year
  • SLS N/A
  • ELA $14.43
  • Revenue Next Year
  • SLS N/A
  • ELA $2.60
  • P/E Ratio
  • SLS N/A
  • ELA $22.41
  • Revenue Growth
  • SLS N/A
  • ELA 24.35
  • 52 Week Low
  • SLS $0.77
  • ELA $5.10
  • 52 Week High
  • SLS $2.27
  • ELA $7.88
  • Technical
  • Relative Strength Index (RSI)
  • SLS 42.73
  • ELA 60.34
  • Support Level
  • SLS $1.65
  • ELA $6.95
  • Resistance Level
  • SLS $2.01
  • ELA $7.50
  • Average True Range (ATR)
  • SLS 0.11
  • ELA 0.32
  • MACD
  • SLS -0.02
  • ELA -0.05
  • Stochastic Oscillator
  • SLS 11.11
  • ELA 69.88

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

Share on Social Networks: